Supplementary Table 1. Tasks Performed during Each Period

Tasks	1st Visit	2nd Visit	3rd Visit	Telephone Call
	Screening		24 Hours	Safety Follow-Up
	Up to 14 Days before	CT Scan	after Iohexol	7 Days after
	CT Scan		Administration	CT Scan ^{††}
Inclusion and exclusion criteria	\checkmark			
Demographic data and medical history	\checkmark			
Physical examination	\checkmark			
Vital signs (including weight and height)	\checkmark	\checkmark		
12-lead ECG	\checkmark	\checkmark		
Pregnancy test*	\checkmark	\checkmark		
Serology [†]	\checkmark			
Urinalysis [‡]	\checkmark			
Laboratory tests: hematology [§] , biochemistry ^{II}	\checkmark		\checkmark	
Blood collection for pharmacokinetic analysis [¶]				
Prior/concomitant medication**	\checkmark		\checkmark	
Record adverse events		\checkmark	\checkmark	
Informed consent	\checkmark			
Randomize to treatment		\checkmark		
Administer iohexol		\checkmark		
CT scan		\checkmark		

*Urine test at screening and on day of CT scan, [†]Tests for hepatitis B surface antigen, hepatitis C, and HIV antibodies, [‡]Urinalysis - pH, protein, glucose, bilirubin, blood, microscopy for cells and casts, [§]Hematology - hemoglobin, packed cell volume, red blood cell count, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count and differential, platelet count, ^{II}Clinical chemistry - sodium, potassium, uric acid, blood urea nitrogen, serum creatinine, total protein, albumin, total bilirubin, ALT, AST, alkaline phosphatase, GGT, non-fasting glucose, [¶]Pharmacokinetic assessments will be performed in subset of subjects in each group at selected centers only. Blood will be collected by intravenous catheter equipped with heplock using NaK3EDTA as anticoagulant at time points: pre-dose, 1, 5, 30, 60 minutes, 2, 4, 6, 8, 10 and 12 hours. Plasma samples will be separated by centrifugation and stored at -70°C until sample analysis. Plasma samples will be shipped to bioanalytical laboratory for iohexol concentration measurements, **Prior medication (over previous 3 months) and continuing medication, ^{††}Subjects who experience delayed adverse reactions following CT scan should contact investigative site immediately. Depending on outcome of safety follow-up, subject may be requested to attend investigative site for additional visit(s) and/or examinations, at investigator's discretion. ALT = alanine transaminase, AST = aspartate aminotransferase, ECG = electrocardiography, GGT = gamma-glutamyl transpeptidase